TinChung Leung
TinChung Leung has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anna M. Stauffer
Weis Center for Research, Geisinger Clinic, Danville, PA 17822, USA
2 shared publicationsHui Chen
Weis Center for Research, Geisinger Clinic, Danville, PA 17822, USA
2 shared publications- Janet D. Robishaw
The Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania, United States of America
2 shared publications Jasper E. Humbert
Weis Center for Research, Geisinger Clinic, Danville, PA 17822, USA
2 shared publicationsKathryn E. Giger
Weis Center for Research, Geisinger Clinic, Danville, PA 17822, USA
2 shared publicationsCarl A. Hansen
From the Weis Center for Research, Geisinger Health System, Danville, PA; and the Department of Biological and Allied Health Sciences, Bloomsburg University, Bloomsburg, PA
1 shared publication
Latest Publications
- 1 November 2008
- Published by Elsevier in Developmental Biology
- Vol. 323 (1) , 31-40
The orphan G protein-coupled receptor 161 is required for left–right patterning
- 1 November 2008
- Published by Elsevier in Developmental Biology
- Vol. 323 (1) , 31-40
The orphan G protein-coupled receptor 161 is required for left–right patterning
- 1 July 2006
- Published by American Society of Hematology in Blood
- Vol. 108 (1) , 160-166
Zebrafish G protein γ2 is required for VEGF signaling during angiogenesis
Vascular endothelial growth factor (VEGF) is a major mediator of pathologic angiogenesis, a process necessary for the formation of new blood vessels to support tumor growth. Historically, VEGF has been thought to signal via receptor tyrosine kinases, which are not typically considered to be G protein dependent. Here, we show that targeted knockdown of the G protein gng2 gene (Gγ2) blocks the normal angiogenic process in developing zebrafish embryos. Moreover, loss of gng2 function inhibits the ability of VEGF to promote the angiogenic sprouting of blood vessels by attenuating VEGF induced phosphorylation of phospholipase C-gamma1 (PLCγ1) and serine/threonine kinase (AKT). Collectively, these results demonstrate a novel interaction between Gγ2- and VEGF-dependent pathways to regulate the angiogenic process in a whole-animal model. Blocking VEGF function using a humanized anti-VEGF antibody has emerged as a promising treatment for colorectal, non-small lung cell, and breast cancers. However, this treatment may cause considerable side effects. Our findings provide a new opportunity for cotargeting G protein- and VEGF-dependent pathways to synergistically block pathologic angiogenesis, which may lead to a safer and more efficacious therapeutic regimen to fight cancer. (Blood. 2006;108:160-166)
- 1 July 2006
- Published by American Society of Hematology in Blood
- Vol. 108 (1) , 160-166
Zebrafish G protein γ2 is required for VEGF signaling during angiogenesis
Vascular endothelial growth factor (VEGF) is a major mediator of pathologic angiogenesis, a process necessary for the formation of new blood vessels to support tumor growth. Historically, VEGF has been thought to signal via receptor tyrosine kinases, which are not typically considered to be G protein dependent. Here, we show that targeted knockdown of the G protein gng2 gene (Gγ2) blocks the normal angiogenic process in developing zebrafish embryos. Moreover, loss of gng2 function inhibits the ability of VEGF to promote the angiogenic sprouting of blood vessels by attenuating VEGF induced phosphorylation of phospholipase C-gamma1 (PLCγ1) and serine/threonine kinase (AKT). Collectively, these results demonstrate a novel interaction between Gγ2- and VEGF-dependent pathways to regulate the angiogenic process in a whole-animal model. Blocking VEGF function using a humanized anti-VEGF antibody has emerged as a promising treatment for colorectal, non-small lung cell, and breast cancers. However, this treatment may cause considerable side effects. Our findings provide a new opportunity for cotargeting G protein- and VEGF-dependent pathways to synergistically block pathologic angiogenesis, which may lead to a safer and more efficacious therapeutic regimen to fight cancer. (Blood. 2006;108:160-166)